Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The closing price of Keros Therapeutics Inc (NASDAQ: KROS) was $13.79 for the day, up 0.29% from the previous closing price of $13.75. In other words, the price has increased by $0.29 from its previous closing price. On the day, 0.5 million shares were traded. KROS stock price reached its highest trading level at $14.39 during the session, while it also had its lowest trading level at $13.75.
Ratios:
Our analysis of KROS’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.78 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.93. For the most recent quarter (mrq), Quick Ratio is recorded 19.29 and its Current Ratio is at 19.29. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Wedbush Downgraded its Outperform to Neutral on January 17, 2025, while the target price for the stock was maintained at $15.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 09 ’25 when ADAR1 Capital Management, LLC bought 934,258 shares for $10.13 per share. The transaction valued at 9,464,512 led to the insider holds 4,392,737 shares of the business.
GORDON CARL L sold 250,000 shares of KROS for $11,002,500 on Aug 13 ’24. The Director now owns 119,522 shares after completing the transaction at $44.01 per share. On Aug 13 ’24, another insider, ORBIMED ADVISORS LLC, who serves as the Director of the company, sold 250,000 shares for $44.01 each. As a result, the insider received 11,002,500 and left with 119,522 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KROS now has a Market Capitalization of 560086336 and an Enterprise Value of -159912224. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.61 while its Price-to-Book (P/B) ratio in mrq is 0.77. Its current Enterprise Value per Revenue stands at -0.745 whereas that against EBITDA is 17.74.
Stock Price History:
The Beta on a monthly basis for KROS is 1.33, which has changed by -0.71690345 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, KROS has reached a high of $72.37, while it has fallen to a 52-week low of $9.12. The 50-Day Moving Average of the stock is -1.46%, while the 200-Day Moving Average is calculated to be -45.44%.
Shares Statistics:
KROS traded an average of 683.00K shares per day over the past three months and 504680 shares per day over the past ten days. A total of 40.56M shares are outstanding, with a floating share count of 33.61M. Insiders hold about 17.24% of the company’s shares, while institutions hold 89.04% stake in the company. Shares short for KROS as of 1749772800 were 4702282 with a Short Ratio of 7.56, compared to 1747267200 on 5772258. Therefore, it implies a Short% of Shares Outstanding of 4702282 and a Short% of Float of 18.14.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
